Tate Thigpen
Impact in
- Reproductive Medicine top 0.5%
- Ovarian cancer diagnosis and treatment
- Obstetrics and Gynecology top 0.5%
- Endometrial and Cervical Cancer Treatments
Papers in
-
- Ovarian cancer diagnosis and treatment 26
-
- Endometrial and Cervical Cancer Treatments 21
- Co-authors
- Jonathan A. LedermannJohn A. BlessingHoward D. HomesleyS. CanevariRalph VanceMichael FriedländerLeo D. LagasseHugh M. Shingleton
- Journals
- Cancer (10 papers)Gynecologic Oncology (4 papers)Annals of Oncology (3 papers)Seminars in Oncology (2 papers)Cancer Investigation (2 papers)
- Partner nations
- United StatesAustraliaUnited Kingdom
In The Last Decade
Tate Thigpen
49 papers receiving 2.8k citations
Hit Papers
Peers
Comparison fields: 5 of 99
- Reproductive Medicine 1.2k
- Obstetrics and Gynecology 891
- Oncology 1.2k
- Pathology and Forensic Medicine 389
- Cancer Research 302
Countries citing papers authored by Tate Thigpen
This map shows the geographic impact of Tate Thigpen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tate Thigpen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tate Thigpen more than expected).
Fields of papers citing papers by Tate Thigpen
This network shows the impact of papers produced by Tate Thigpen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tate Thigpen. The network helps show where Tate Thigpen may publish in the future.
Co-authors
The 25 scholars most cited alongside Tate Thigpen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 259 | |
| 2 | 2012 | 27 | |
| 3 | Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) Hit paper breakdown → | 2011 | 452 |
| 4 | 2010 | 73 | |
| 5 | 2006 | 11 | |
| 6 | 2005 | 31 | |
| 7 | 2005 | 5 | |
| 8 | 2004 | 20 | |
| 9 | 2003 | 46 | |
| 10 | 2002 | 14 | |
| 11 | 1997 | 5 | |
| 12 | The role of ifosfamide and systemic therapy in the management of carcinoma of the cervix. | 1996 | 9 |
| 13 | 1995 | 19 | |
| 14 | 1994 | 48 | |
| 15 | 1987 | 59 | |
| 16 | 1982 | 37 | |
| 17 | 1981 | 56 | |
| 18 | 1979 | 26 | |
| 19 | Evaluation of VP-16-213 in malignant lymphoma and melanoma. | 1978 | 29 |
| 20 | Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. | 1976 | 114 |
About Tate Thigpen
Tate Thigpen is a scholar working on Reproductive Medicine, Obstetrics and Gynecology, Oncology, Cancer Research and Pathology and Forensic Medicine, having authored 49 papers that have together received 2.9k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (26 papers), Endometrial and Cervical Cancer Treatments (21 papers), Intraperitoneal and Appendiceal Malignancies (6 papers), Cancer Treatment and Pharmacology (6 papers), Lymphoma Diagnosis and Treatment (5 papers), Reproductive Biology and Fertility (4 papers), Colorectal and Anal Carcinomas (4 papers) and Cervical Cancer and HPV Research (3 papers). The work is most often cited by research in Reproductive Medicine (1.2k citations), Obstetrics and Gynecology (891 citations), Oncology (1.2k citations), Pathology and Forensic Medicine (389 citations) and Cancer Research (302 citations). Tate Thigpen has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Jonathan A. Ledermann, John A. Blessing, Howard D. Homesley, S. Canevari, Ralph Vance, Michael Friedländer, Leo D. Lagasse, Hugh M. Shingleton, Tawfiq Khansur and R Bottomley. Their work appears in journals such as Cancer, Gynecologic Oncology, Annals of Oncology, Seminars in Oncology and Cancer Investigation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.